Radformation, Inc.

Radformation, Inc. develops automation software to enhance operational efficiency and safety in cancer treatment clinics, streamlining workflows and improving patient care through innovative solutions. Founded in 2016, Radformation, Inc. is headquartered in New York, US, and specializes in creating software that optimizes cancer treatment planning.

The company was co-founded by Alan Nelson, Elisabeth Van Wie, and Kurt Sysock, with Kurt Sysock serving as the CEO. Radformation has successfully closed 5 deals, with its most recent investment round being a Series A, which raised USD 6. 85 mn from Bessemer Venture Partners on May 12, 2023, bringing the total amount raised to USD 6. 85 mn and a current company valuation of USD 145.

69 mn. Radformation specializes in automation software designed for cancer treatment clinics, focusing on enhancing plan quality, safety, and operational efficiency. Their core product offerings include AutoContour, which automates the creation of deep-learning contours for radiation therapy; EZFluence, which generates high-quality 3D treatment plans; and ClearCheck, which provides one-click evaluation tools for treatment plans. Each product addresses specific challenges faced by clinics, such as the need for rapid processing of complex treatment plans and the efficient management of documentation and billing procedures.

The company serves a diverse client base that includes prominent cancer treatment centers and universities worldwide, such as the University of California San Diego and the BC Cancer Agency, enabling them to streamline workflows and improve patient care. Radformation’s solutions are marketed in various geographical regions, including North America, Europe, and parts of Asia, ensuring a wide reach in the healthcare technology landscape. Radformation generates revenue primarily through direct sales of its software solutions to cancer treatment facilities, often structured as subscription-based models. Clients engage with the company's offerings through annual or multi-year contracts, which provide ongoing access to software updates and customer support.

The pricing structure typically reflects the comprehensive nature of their flagship products, such as the automated contouring and planning software, designed to integrate seamlessly with existing treatment planning systems like Eclipse™ TPS. Revenue is influenced by the volume of transactions between Radformation and medical facilities, where clinics deploy multiple products to optimize their treatment planning workflows. By providing a suite of tools that enhance operational efficiency, Radformation positions itself as an essential partner in the healthcare technology ecosystem, supporting the ongoing needs of its clients in delivering high-quality care to patients. Following the Series A funding round completed on May 12, 2023, Radformation, Inc.

plans to utilize the USD 6. 85 mn raised to accelerate the development of its AI-driven cancer care solutions. The company is focused on launching new products to further enhance its offerings and aims to expand into additional geographic regions, targeting markets in Asia and Europe by late 2024. This strategic growth will help Radformation to continue improving operational efficiency for cancer clinics globally.